TipRanks
Advertisement
Advertisement

HK:2509 Stock Latest News

Qyuns Therapeutics’ Oturkibart Shows Strong Phase III PN Data at EADV 2026
Company AnnouncementsQyuns Therapeutics’ Oturkibart Shows Strong Phase III PN Data at EADV 2026
11d ago
2509
Qyuns Therapeutics Updates Board Composition and Governance Structure
PremiumCompany Announcements
Qyuns Therapeutics Updates Board Composition and Governance Structure
20d ago
2509
Qyuns Therapeutics Raises QX001S Deal Caps and Refreshes Board Line-Up
PremiumCompany Announcements
Qyuns Therapeutics Raises QX001S Deal Caps and Refreshes Board Line-Up
20d ago
2509
Qyuns Therapeutics Swings to Interim Profit on Surging Licensing Revenue
PremiumCompany Announcements
Qyuns Therapeutics Swings to Interim Profit on Surging Licensing Revenue
2M ago
2509
Qyuns Therapeutics Sets Board Meeting to Approve 2026 Interim Results
PremiumCompany Announcements
Qyuns Therapeutics Sets Board Meeting to Approve 2026 Interim Results
2M ago
2509
Qyuns Therapeutics Wins New QX027N Trial Approvals and Secures Global Licensing Deal
PremiumCompany AnnouncementsQyuns Therapeutics Wins New QX027N Trial Approvals and Secures Global Licensing Deal
2M ago
2509
Caldera-Synlogic Merger and $278 Million Raise Bolster Qyuns-Linked IBD Program
Premium
Company Announcements
Caldera-Synlogic Merger and $278 Million Raise Bolster Qyuns-Linked IBD Program
3M ago
2509
Qyuns Therapeutics to Fully Acquire Cellularforce in RMB86 Million Connected Deal
Premium
Company Announcements
Qyuns Therapeutics to Fully Acquire Cellularforce in RMB86 Million Connected Deal
4M ago
2509
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
PremiumCompany Announcements
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
4M ago
2509
Qyuns Therapeutics Shareholders Unanimously Approve AGM Resolutions
PremiumCompany Announcements
Qyuns Therapeutics Shareholders Unanimously Approve AGM Resolutions
5M ago
2509
Qyuns Therapeutics Hits Roche Milestone as QX031N Enters Phase I Trial
PremiumCompany Announcements
Qyuns Therapeutics Hits Roche Milestone as QX031N Enters Phase I Trial
5M ago
2509
Qyuns Therapeutics Wins China Approval for Ustekinumab in Crohn’s Disease
PremiumCompany Announcements
Qyuns Therapeutics Wins China Approval for Ustekinumab in Crohn’s Disease
5M ago
2509
Qyuns Therapeutics Sets 2025 AGM to Approve Reports, Profit Plan and Share Issuance Mandate
PremiumCompany AnnouncementsQyuns Therapeutics Sets 2025 AGM to Approve Reports, Profit Plan and Share Issuance Mandate
5M ago
2509
Qyuns Therapeutics Invests RMB270 Million in Low-Risk PDB Wealth Products
Premium
Company Announcements
Qyuns Therapeutics Invests RMB270 Million in Low-Risk PDB Wealth Products
6M ago
2509
Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
Premium
Company Announcements
Qyuns Therapeutics Swings to Profit on Surging 2025 Revenue and Stronger Balance Sheet
7M ago
2509
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
PremiumCompany Announcements
Qyuns Therapeutics Forms Strategy and Development Committee to Sharpen Long-Term Planning
7M ago
2509
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
PremiumCompany Announcements
Qyuns Therapeutics Tightens Audit Committee Mandate to Bolster Governance
7M ago
2509
Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
PremiumCompany Announcements
Qyuns Therapeutics Sets Up Board Committee to Overhaul Executive Pay Oversight
7M ago
2509
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
PremiumCompany Announcements
Qyuns Therapeutics Sets Up Nomination Committee to Bolster Governance
7M ago
2509
Qyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
PremiumCompany AnnouncementsQyuns Therapeutics Invests RMB100 Million in Low-Risk Wealth Management Product
7M ago
2509
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
Premium
Company Announcements
Qyuns Therapeutics Sets March Board Meeting to Approve 2025 Results and Consider Dividend
7M ago
2509
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
Premium
Company Announcements
Qyuns Therapeutics’ Ankylosing Spondylitis Drug Crusekitug Wins NDA Acceptance in China
7M ago
2509

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >